8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report
(Date of earliest event          October 5, 2004
reported)

                             BSD MEDICAL CORPORATION
             ------------------------------------------------------
             (Exact name of registrant as specified in its charter)

          Delaware                       0-10783                 75-1590407
- ----------------------------           -----------            ----------------
(State or other jurisdiction           (Commission            (I.R.S. Employer
      of incorporation)                File Number)          Identification No.)

       2188 West 2200 South
        Salt Lake City, Utah                                       84119
- ----------------------------------------                         ----------
(Address of principal executive offices)                         (Zip Code)

        Registrant's telephone number, including area code (801) 972-5555

                                       N/A
- --------------------------------------------------------------------------------
         (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

|_| Written communications pursuant to Rule 425 under the Securities Act
    (17 CFR 230.425)

|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act
    (17 CFR 240.14a-12)

|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act CFR 240.14d-2(b))

|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
    Act (17 CFR 240.13a-4(c))



Item 9.01 Financial Statements and Exhibits.

      (c) Exhibits

99.1  Press Release of BSD Medical Corporation dated October 5, 2004.

Item 7.01 Regulation FD Disclosure.

      BSD Medical Corporation issued a press release on October 5, 2004. A copy
of the press release is hereby furnished as Exhibit 99.1 attached hereto.



                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Dated: October 5, 2004

                                                          By: /s/  Hyrum A. Mead
                                                              ------------------
                                                              President



                                  EXHIBIT INDEX

Exhibit No.                        Description
- -----------  -------------------------------------------------------------------
99.1         Press Release of BSD Medical Corporation dated October 5, 2004.

EX-99.1

                                                                    Exhibit 99.1

      BSD Medical Corp. Sponsors Symposium and Displays Products at ASTRO

    ATLANTA, Oct. 5 /PRNewswire-FirstCall/ -- BSD Medical Corp.
(OTC Bulletin Board: BSDM) today announced that it is pursuing an aggressive
agenda for the 49th annual meeting of the American Society for Therapeutic
Radiology and Oncology (ASTRO) being convened October 3-7 in Atlanta.  ASTRO
is the premier annual educational and scientific event for radiation oncology
professionals held in the United States, and attracts about 9,000 attendees
from all over the world.

    On October 2, the evening before ASTRO opened, BSD sponsored a symposium
dedicated to the treatment of recurrent cancer using a combination of
hyperthermia and radiation therapy.  A distinguished panel of radiation
oncologists spoke at the two-hour symposium, which was attended by invited
guests.  Dr. Arve Gillette, past President of the American College of
Radiation Oncology, and Dr. John Kalapurakal of Northwestern University
addressed groundbreaking work in the treatment of recurrent prostate cancer.
Dr. Ellen Jones of Duke University lectured on innovations in the treatment of
recurrent breast cancer.  Dr. Nisar Syed, Chief of Radiation Oncology at Long
Beach Memorial Medical Center, spoke on breakthroughs in the treatment of head
and neck cancer.

    BSD Medical is simultaneously presenting two commercial exhibits at the
Georgia World Congress Center where ASTRO is convened.  One exhibit is
promoting the BSD-500 and its capabilities for treating superficial cancers,
and cancers that can be approached through interstitial therapies.  The second
exhibit is dedicated to the BSD-2000 and all of its capabilities, including
integration with magnetic resonance imaging systems to provide 3D non-invasive
visual monitoring of hyperthermia treatments in progress.


    BSD Medical Corporation is the leading developer of microwave systems used
in thermal medicine for the treatment of cancer.  Hyperthermia therapy is used
in combination with radiation and/or chemotherapy to boost local control of
cancer and increase long-term survival.  For more information about BSD
Medical Corp. visit www.BSDMC.com.


    Statements contained in this press release that are not historical facts
are forward looking statements, as that item is defined in the Private
Securities Litigation Reform Act of 1995.  All forward-looking statements are
subject to risks and uncertainties, some of which are detailed in part in the
Company's filings with the Securities and Exchange Commission.



SOURCE  BSD Medical Corp.
    -0-                             10/05/2004
    /CONTACT:  Hyrum A. Mead of BSD Medical Corp., +1-801-972-5555, fax,
+1-801-972-5930, investor@bsdmc.com/
    /Web site:  http://www.bsdmc.com /
    (BSDM)

CO:  BSD Medical Corp.
ST:  Georgia
IN:  HEA MTC BIO OTC
SU:  TDS